We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bioseek | LSE:ATD | London | Ordinary Share | GB0009231639 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMATD
RNS Number : 2952C
Asterand PLC
30 April 2012
For Immediate Release 30 April 2012
Asterand plc
FINAL RESULTS STATEMENT
for the year ended 31 December 2011
Asterand plc (LSE: ATD), a leading global supplier of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery research, announces its audited final financial results for the year ended 31 December 2011.
The full 2011 Annual Report and Accounts can be found on our website at
http://www.asterand.com/Asterand/investors/financialreports/2012/Asterand_Annual_Report_Accounts_2011.pdf
Notes to Editors
Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and drug compound validation and enable our clients to take safer and more effective drugs into the market.
For more information about Asterand please visit http://www.asterand.com
For further information contact:
Contacts:
Asterand plc Jack Davis, Chairman, Interim Chief Executive Officer and Tel: + 44 (0) 1763 211 600 / Company Secretary Tel: + 1 (313) 263-0960 Alan Fishman, Interim Chief Financial As above Officer Daniel Stewart & Company plc Antony Legge Tel: +44 (0) 20 7776 6550
CHAIRMAN'S STATEMENT
Results for the year ended 31 December 2011
During 2011 the Group achieved revenue of $24.09 million (2010: $21.31 million), an increase of 13%. These results were due to strong annual performance by the BioSeek business and benefited as well from the inclusion of a full twelve months of BioSeek in 2011 (2010: ten months) and an improved 4(th) quarter performance by the non-BioSeek related Tissue Based Solutions business.
The Group's cost of sales was $11.23 million (2010: $9.33 million), leading to a gross profit for the year of $12.86 million (2010: $11.98 million profit). As a result, gross margins were 53% (2010: 56%).
This revenue growth was achieved while prudently managing costs and keeping expenditures on normal operations in check. Research and Development (R&D) expenses were $1.43 million (2010: $1.33 million). All 2011 R&D expenses were related to improvements to new product offerings to support the Group's focus on the business of human tissue supply and human tissue based solutions.
Selling and distribution costs were $3.41 million (2010: $3.82 million). These costs relate to sales staff salaries, commissions and marketing expenses. The modest decrease is attributable to a reduction in sales staff salaries expense due to attrition and a renegotiation of our consultant agreement with our Japanese sales and marketing representative.
Total general and administrative expenses were $12.55 million (2010: $8.92 million). General and administrative expenses are analysed between those relating to exceptional costs and those to normal operations. Costs relating to normal operations were reduced to $7.82 million (2010: $8.00 million).
On 24 October 2011 the commencement of a formal sales process for the Group was announced. During this process the Group has held discussions with several interested parties. The Company has not been able to secure an offer for the whole Group, instead it has signed letters of intent for each of the two businesses in the Tissue Based Solutions segment: BioSeek and the non-BioSeek Tissue Based Solutions. As a consequence, the formal sale process has now ended and the Company is no longer in an Offer Period.
This decision, after the year end, to sell certain elements of the business separately has resulted in reductions in the carrying value of certain assets, primarily intangible assets and inventory, as explained further below. These impairment charges reflect that these financial statements are not prepared on a going concern basis since all parts of the business are being actively marketed and thus the asset values have been adjusted to reflect their estimated realisable value.
Exceptional general and administrative costs rose to $4.73 million (2010: $0.92 million) due to these impairment charges, totalling $3.40 million. Remaining exceptional costs related to severance, acquisition, litigation and sale costs.
The Group realised a $8.23 million loss for the year (2010: $2.07 million loss), including a $1.59 million (2010: $nil) exceptional interest expense relating to the financing arrangements in place to acquire BioSeek. Loan notes were the agreed form of payment for the contingent consideration of BioSeek; the interest expense arising on these are deemed to be exceptional interest.
Although it is a non-IFRS measure, Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and excluding exceptional items and share option related charges is monitored closely by the Directors and management as a metric to measure progress of business operations towards profitability and positive cash flow. The adjusted EBITDA for 2011 was $1.51 million profit, a $1.53 million improvement over 2010 (2010: $0.02 million loss). An explanation of this calculation can be found on page 6 of this document.
Balance Sheet
At 31 December 2011, the carrying value of the intangible assets was reduced to $3.31 million due to an impairment charge of $1.29 million to write down the carrying value of the assets of the non-BioSeek related Tissue Based Solutions business to a level of the expected net proceeds from the business disposal.
On 31 December 2011, the carrying value of the biobank inventory was reduced to $6.55 million due to an impairment charge of $2.11 million to write down the carrying value of inventory to the amount implied by the expected recoverable amounts in the sale of the non-BioSeek Tissue Based Solutions business.
Cash flows
The Directors monitor the cash flow and cash resources closely. At 31 December 2011, there had been a $2.94 million reduction in the cash balance as compared to the previous year (2011: $2.98 million; 2010: $5.92 million). Primary uses of cash throughout the year included $3.24 million debt and finance lease repayments and $0.72 million of loan interest paid.
Financing and liquidity
At 31 December 2011 the Group had cash and cash equivalents of $2.98 million (2010: $5.92 million). The Group has a $2.30 million term loan with Silicon Valley Bank and a $6.59 million balance on the loan note with the former BioSeek shareholders. In October 2011, the Group received notification that these loans were in default. As announced in October 2011, the Company is currently undergoing a formal sale of all or part of the business. Our creditors have remained supportive throughout and we believe the default status will be resolved at the conclusion of the sales process.
Board changes and corporate governance
During 2011 we announced the departures of Martyn Coombs, the Group's Chief Executive Officer, John Stchur, the Group's Chief Financial Officer and Jonathan Fleming, a Non-Executive Director.
I'd like to take this opportunity to thank Martyn, John and Jonathan for their service over the past years and wish them well in their future endeavours.
The Board and management continue to have a policy of transparency with regards to our strategy and related activities. An important component of this involves communicating and listening to our shareholders to understand their ideas and points of view.
Aligning objectives between employees and shareholders
During 2011, we granted a total of 0.92 million share options to our employees through our Long Term Incentive Programme. We believe this programme enables us to retain key employees, while aligning the goals of our shareholders with those of our employees. Every Asterand employee receives shares under this programme.
Outlook
As previously mentioned, the Group commenced a formal sale process for the issued capital of the Group in October 2011. The Company has instead signed letters of intent to sell each of the two businesses: BioSeek and the non-BioSeek Tissue Based Solutions business, separately, and the formal sale process has ended with the Company now no longer in an Offer Period.
Assuming that definitive agreements are executed the Board is expecting to issue a circular to shareholders in the coming weeks with details of the proposed transactions. Then the likely process will be disposal of the assets of each of the two businesses and a solvent liquidation of the Group to return cash to shareholders. Whilst the level of a liquidation dividend, if any, cannot definitely be determined at this time, the Board's current estimation, based on the letters of interest from the buyers and the current share price, is that the maximum payout to shareholders is unlikely to show a significant premium to the share price as of the close of business on 26 April 2012.
Revenue for the non-BioSeek portions of the Tissue Based Solutions business, which had been volatile for most of the year, stabilised in the last quarter of 2011, providing an increased cash flowover the original estimates. Given these factors, the Directors have a reasonable expectation that the Company will maintain adequate resources to continue in operational existence until completion of disposals. The completion of the disposals is not guaranteed and there is inherent risk that the sale cannot be completed within the necessary timeframe. In addition, the following are considered to be further uncertainties related to the disposals:
-- Shareholder approval - raising funds through the disposals of all or part of the Company's assets is predicated on shareholder approval. The Board intends to convene an Extraordinary General Meeting at which the necessary resolutions will be put to shareholders. While there is uncertainty over the outcome of these votes, the Board has a reasonable expectation that approval to proceed with this strategy will be forthcoming.
-- Loan covenants - we are currently in default of our Silicon Valley Bank and former shareholders of BioSeek loans. We have been in communication with our lenders and they are in support of resolving the default status at the conclusion of this process. However, their continued support cannot be guaranteed.
-- Trading results - management have prepared budgets and projections which they believe are prudent and achievable. However, the achievement of these trading results is uncertain.
Given that the Directors have resolved to sell the two business units separately, a 'going concern' presumption in IAS 1 is not appropriate; therefore the accounts have been drawn up on a basis which reflects the Directors' intention to sell the two business units. The management team continues to tightly control operating expenses to maintain sufficient working capital. In addition, based on discussions with potential purchasers, the Board believes that it has a reasonable expectation that the disposals will be completed within an appropriate timeframe.
Jack Davis
Chairman, Asterand plc
Consolidated Income Statement
for the year ended 31 December 2011
Hot Features
Premium
2011 2010
Note $'000 $'000
-------------------------------------------- ----- --------- ---------
Revenue 2 24,091 21,310
-------------------------------------------- ----- --------- ---------
Cost of sales (11,233) (9,332)
-------------------------------------------- ----- --------- ---------
Gross profit 12,858 11,978
-------------------------------------------- ----- --------- ---------
Research and development costs (1,432) (1,326)
-------------------------------------------- ----- --------- ---------
Selling and distribution costs (3,412) (3,824)
-------------------------------------------- ----- --------- ---------
-Normal operations (7,819) (8,003)
-------------------------------------------- ----- --------- ---------
-Exceptional items (impairment, severance,
acquisition, litigation and sale costs) 3 (4,733) (920)
-------------------------------------------- ----- --------- ---------
Total general and administrative expenses (12,552) (8,923)
-------------------------------------------- ----- --------- ---------
Total operating expenses (17,396) (14,073)
-------------------------------------------- ----- --------- ---------
Operating loss (4,538) (2,095)
-------------------------------------------- ----- --------- ---------
Interest income - normal operations 78 4
-------------------------------------------- ----- --------- ---------
Interest expense - normal operations (716) (57)
-------------------------------------------- ----- --------- ---------
Interest expense - exceptional costs (1,591) -
-------------------------------------------- ----- --------- ---------
Foreign exchange credit 166 107
-------------------------------------------- ----- --------- ---------
Finance (expense)/income (2,063) 54
-------------------------------------------- ----- --------- ---------
Loss before taxation (6,601) (2,041)
-------------------------------------------- ----- --------- ---------
Taxation (1,627) (32)
-------------------------------------------- ----- --------- ---------
Loss for the financial year attributable
to owners of the parent (8,228) (2,073)
-------------------------------------------- ----- --------- ---------
Loss per 5p ordinary share
-------------------------------------------- ----- --------- ---------
Basic 4 (7.0)c (1.8)c
-------------------------------------------- ----- --------- ---------
Diluted 4 (7.0)c (1.8)c
-------------------------------------------- ----- --------- ---------
Consolidated Statement of Comprehensive Income
for the year ended 31 December 2011
Group Group
2011 2010
$'000 $'000
-------------------------------------------------- -------- --------
Loss for the financial year (8,228) (2,073)
-------------------------------------------------- -------- --------
Other comprehensive income:
-------------------------------------------------- -------- --------
Exchange translation difference on consolidation
recognised directly in equity (183) (66)
-------------------------------------------------- -------- --------
Other comprehensive expense for the year net of
tax (183) (66)
-------------------------------------------------- -------- --------
Total comprehensive expense for the year (8,411) (2,139)
-------------------------------------------------- -------- --------
There is no tax arising on the exchange translation difference on consolidation recognised directly in equity.
Non-IFRS Measure
Earnings before interest, taxes, depreciation and amortisation ("EBITDA") - and excluding exceptional items and share option related charge for the year ended 31 December 2011:
2011 2010
$'000 $'000
-------------------------------------------------------- --- -------- --------
Operating loss (4,538) (2,095)
------------------------------------------------------------- -------- --------
Exceptional items (impairment, severance, acquisition,
litigation and sale costs) 4,733 920
------------------------------------------------------------- -------- --------
Share option related charge 230 132
------------------------------------------------------------- -------- --------
Depreciation and amortisation 1,084 1,022
------------------------------------------------------------- -------- --------
Adjusted EBITDA 1,509 (21)
------------------------------------------------------------- -------- --------
Consolidated Balance Sheet
as at 31 December 2011
2011 2010
Note $'000 $'000
--------------------------------------------------------------------- --- ----- -------------- ---------
Assets
--------------------------------------------------------------------- --- ----- -------------- ---------
Non-current assets
--------------------------------------------------------------------- --- ----- -------------- ---------
Intangible assets 5 3,305 4,778
-------------------------------------------------------------------------- ----- -------------- ---------
Property, plant and equipment 2,959 3,386
-------------------------------------------------------------------------- ----- -------------- ---------
Deferred tax asset 4,360 4,843
-------------------------------------------------------------------------- ----- -------------- ---------
Trade and other receivables 90 94
-------------------------------------------------------------------------- ----- -------------- ---------
10,714 13,101
------------------------------------------------------------------------- ----- -------------- ---------
Current assets
--------------------------------------------------------------------- --- ----- -------------- ---------
Biobank inventory 7 6,549 9,136
-------------------------------------------------------------------------- ----- -------------- ---------
Trade and other receivables 6,130 6,216
-------------------------------------------------------------------------- ----- -------------- ---------
Cash and cash equivalents 2,978 5,918
-------------------------------------------------------------------------- ----- -------------- ---------
15,657 21,270
------------------------------------------------------------------------- ----- -------------- ---------
Liabilities
--------------------------------------------------------------------- --- ----- -------------- ---------
Current liabilities
--------------------------------------------------------------------- --- ----- -------------- ---------
Trade and other payables (6,857) (5,250)
-------------------------------------------------------------------------- ----- -------------- ---------
Income tax payable (1,307) (797)
-------------------------------------------------------------------------- ----- -------------- ---------
Other financial liabilities --Finance
leases 8 (5) (12)
-------------------------------------------------------------------------- ----- -------------- ---------
--Current debt 8 (2,428) (703)
-------------------------------------------------------------------------- ----- -------------- ---------
--Amounts due to former shareholders
of BioSeek 8 (6,591) (7,624)
-------------------------------------------------------------------------- ----- -------------- ---------
--Warrants 8 (12) -
-------------------------------------------------------------------------- ----- -------------- ---------
(17,200) (14,386)
------------------------------------------------------------------------- ----- -------------- ---------
Net current (liabilities)/assets (1,543) 6,884
-------------------------------------------------------------------------- ----- -------------- ---------
Non-current liabilities
--------------------------------------------------------------------- --- ----- -------------- ---------
Deferred tax liability (179) (282)
-------------------------------------------------------------------------- ----- -------------- ---------
Other financial liabilities --Finance
leases 8 - (5)
-------------------------------------------------------------------------- ----- -------------- ---------
--Long term debt 8 - (2,348)
-------------------------------------------------------------------------- ----- -------------- ---------
Other payables (1,778) (2,191)
-------------------------------------------------------------------------- ----- -------------- ---------
(1,957) (4,826)
------------------------------------------------------------------------- ----- -------------- ---------
Net assets 7,214 15,159
-------------------------------------------------------------------------- ----- -------------- ---------
Equity attributable to owners of the
parent
--------------------------------------------------------------------- --- ----- -------------- ---------
Ordinary shares 9,428 9,262
-------------------------------------------------------------------------- ----- -------------- ---------
Shares to be issued 8 535
-------------------------------------------------------------------------- ----- -------------- ---------
Share premium 84,676 84,298
-------------------------------------------------------------------------- ----- -------------- ---------
Reverse acquisition reserve (66,757) (66,757)
-------------------------------------------------------------------------- ----- -------------- ---------
Merger reserve 510 510
-------------------------------------------------------------------------- ----- -------------- ---------
Other reserves 4,910 4,910
-------------------------------------------------------------------------- ----- -------------- ---------
Profit and loss reserve (29,928) (22,149)
-------------------------------------------------------------------------- ----- -------------- ---------
Currency translation reserve 4,367 4,550
-------------------------------------------------------------------------- ----- -------------- ---------
Total equity 7,214 15,159
-------------------------------------------------------------------------- ----- -------------- ---------
Company Balance Sheet
as at 31 December 2011
2011 2010
Note $'000 $'000
----------------------------------- ---- -------- --------
Assets
----------------------------------- ---- -------- --------
Non-current assets
----------------------------------- ---- -------- --------
Investment in subsidiaries 6 21,617 24,574
--------------------------------------- ---- -------- --------
Amounts receivable from Group
companies 9 - 3,001
--------------------------------------- ---- -------- --------
21,617 27,575
-------------------------------------- ---- -------- --------
Current assets
----------------------------------- ---- -------- --------
Trade and other receivables 227 161
--------------------------------------- ---- -------- --------
Cash and cash equivalents 10 10
--------------------------------------- ---- -------- --------
237 171
-------------------------------------- ---- -------- --------
Liabilities
----------------------------------- ---- -------- --------
Current liabilities
----------------------------------- ---- -------- --------
Trade and other payables (207) (22)
--------------------------------------- ---- -------- --------
Amounts due to former shareholders
of BioSeek 10 (6,591) (7,624)
--------------------------------------- ---- -------- --------
Amounts payable to Group companies 9 (2,329) -
--------------------------------------- ---- -------- --------
(9,127) (7,646)
-------------------------------------- ---- -------- --------
Net current liabilities (8,890) (7,475)
--------------------------------------- ---- -------- --------
Net assets 12,727 20,100
--------------------------------------- ---- -------- --------
Equity attributable to owners
of the parent
----------------------------------- ---- -------- --------
Ordinary shares 9,428 9,262
--------------------------------------- ---- -------- --------
Shares to be issued 8 535
--------------------------------------- ---- -------- --------
Share premium 84,676 84,298
--------------------------------------- ---- -------- --------
Merger reserve 510 510
--------------------------------------- ---- -------- --------
Retained losses (92,548) (85,165)
--------------------------------------- ---- -------- --------
Currency translation reserve 10,653 10,660
--------------------------------------- ---- -------- --------
Total equity 12,727 20,100
--------------------------------------- ---- -------- --------
Consolidated Statement of Changes in Equity
as at 31 December 2011
Profit Currency
Shares Reverse Investment and translation
Ordinary to be Share acquisition Merger Other in own loss reserve Total
shares issued premium reserve reserve reserves shares reserve $'000 equity
Group $'000 $'000 $'000 $'000 $'000 $'000 $'000 $'000 $000
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
At 1 January
2010 9,043 5 84,282 (66,757) --- 4,910 (1,062) (18,434) 4,616 16,603
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Comprehensive - -
Income
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Loss for the
year - - - - - - - (2,073) - (2,073)
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Other
comprehensive
income
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Exchange
translation - - - - - - - - (66) (66)
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Total
Comprehensive
Income - - - - - - - (2,073) (66) (2,139)
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Employee share
option schemes
Value of
employee
services - - - - - - - 132 - 132
Proceeds from
shares issued 6 - 16 - - - - - - 22
Modification
to equity
settled share
option scheme - - - - - - - (187) - (187)
Proceeds from
shares issued - 530 - - - - (525) - - 5
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Acquisition
of BioSeek 213 - - - 510 - - - - 723
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Transactions
with owners 219 530 16 - 510 - (525) (55) - 695
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
At 31 December
2010 9,262 535 84,298 (66,757) 510 4,910 (1,587) (20,562) 4,550 15,159
Comprehensive
Income
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Loss for the
year - - - - - - - (8,228) - (8,228)
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Other
comprehensive
income
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Exchange
translation - - - - - - - - (183) (183)
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Total
Comprehensive
Income - - - - - - - (8,228) (183) (8,411)
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Employee share
option schemes
Value of
employee
services - - - - - - - 403 - 403
Proceeds from
shares issued 166 (527) 378 - - - 46 - - 63
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Transactions
with owners 166 (527) 378 - - - 46 403 - 466
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
At 31 December
2011 9,428 8 84,676 (66,757) 510 4,910 (1,541) (28,387) 4,367 7,214
--------------- --------- ------- -------- ------------ -------- --------- ----------- --------- ------------ --------
Included within the investment in own shares reserve are 304,037 (2010: 419,231) shares of 5p each held by the 2007 Employee Ownership Plan Trust ('2007 EOPT') for the satisfaction of share obligations under all option plans. The costs of funding and administering the 2007 EOPT are charged to the income statement of the Group in the period to which they relate. At 31 December 2011, the shares owned by the 2007 EOPT had a market value of $11,159 (2010: $176,981).
Other reserves represent the merger reserve arising on consolidation, being the share capital and share premium account balances of Pharmagene Laboratories Limited (renamed Asterand UK Limited) less the nominal value of the shares issued by the Company to acquire these shares, before the merger with Pharmagene plc (renamed Asterand plc) prior to the initial public offering of the Company in 2000.
The merger reserve represents the premium to the nominal value of the shares issued on the acquisition of BioSeek during 2010.
In 2010, a modification was made to an equity settled share option scheme (2007 LTIP options) to settle this partly in cash to allow US employees to settle their US tax liability on US vested options. This resulted in a charge of $187,000 being recorded through reserves (2011: $nil).
Company Statement of Changes in Equity
as at 31 December 2011
Profit
Shares and Currency
Ordinary to Share Merger loss translation Total
shares be issued premium reserve reserve reserve equity
$'000 $'000 $'000 $'000 $'000 $'000 $'000
----------------------- -------- ---------- -------- -------- -------- ------------ --------
At 1 January 2010 9,043 5 84,282 - (83,140) 10,810 21,000
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Comprehensive income
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Loss for the year - - - - (1,970) - (1,970)
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Other comprehensive
income
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Exchange translation - - - - - (150) (150)
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Total comprehensive
income - - - - (1,970) (150) (2,120)
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Employee share option
schemes
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Value of employee
services - - - - 67 - 67
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Capital contribution - - - - 65 - 65
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Proceeds from shares
issued 6 - 16 - - - 22
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Modification to
equity settled share
option scheme - - - - (187) - (187)
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Shares to be issued - 530 - - - - 530
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Acquisition of BioSeek 213 - - 510 - - 723
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Transactions with
owners 219 530 16 510 (55) - 1,220
----------------------- -------- ---------- -------- -------- -------- ------------ --------
At 1 January 2011 9,262 535 84,298 510 (85,165) 10,660 20,100
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Comprehensive income
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Loss for the year - - - - (7,786) - (7,786)
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Other comprehensive
income
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Exchange translation - - - - - (7) (7)
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Total comprehensive
income - - - - (7,786) (7) (7,793)
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Employee share option
schemes
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Value of employee
services - - - - 289 - 289
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Capital contribution - - - - 114 - 114
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Proceeds from shares
issued 166 (527) 378 - - - 17
----------------------- -------- ---------- -------- -------- -------- ------------ --------
Transactions with
owners 166 (527) 378 - 403 - 420
----------------------- -------- ---------- -------- -------- -------- ------------ --------
At 31 December 2011 9,428 8 84,676 510 (92,548) 10,653 12,727
----------------------- -------- ---------- -------- -------- -------- ------------ --------
See Consolidated Statement of Changes in Equity for explanation of changes in equity.
Consolidated Cash Flow Statement
for the year ended 31 December 2011
2011 2010
$'000 $'000
Note
------------------------------------------------- ----- -------- --------
Cash flows from operating activities
Loss for the year (8,228) (2,073)
Adjustments for:
Contingent consideration remeasurement - 356
Finance expense/(income) 2,063 (54)
Tax charge 1,627 32
Depreciation of property, plant and equipment 865 827
Amortisation of intangible assets 5 219 195
Share option compensation charge 403 132
Impairment charge 3 3,400 -
Operating cash flows before movement
in working capital 349 (585)
------------------------------------------------- ----- -------- --------
Decrease/(increase) in trade and other
receivables 75 (2,242)
Decrease/(increase) in biobank inventories 7 480 (318)
Increase/(decrease) in trade and other
payables 1,194 (1,570)
------------------------------------------------- ----- -------- --------
Cash used in operations 2,098 (4,715)
------------------------------------------------- ----- -------- --------
Interest received 78 4
Interest paid (716) (53)
Interest element of finance lease rental
payments (2) (4)
Income taxes paid (763) (120)
Receipt of research and development tax 87 -
credit
------------------------------------------------- ----- -------- --------
Net cash used in operating activities 782 (4,888)
------------------------------------------------- ----- -------- --------
Cash flows from investing activities
Cash acquired on acquisition of BioSeek 10 - 1,573
Purchase of property, plant and equipment (457) (311)
Purchase of intangible assets 5 (35) (64)
------------------------------------------------- ----- -------- --------
Net cash (used in)/generated from investing
activities (492) 1,198
------------------------------------------------- ----- -------- --------
Cash flows from financing activities
Proceeds from issue of ordinary share
capital 14 22
Proceeds from ordinary share capital
to be issued - 5
Loan received - 2,948
Debt and finance lease principal payments (3,244) (11)
------------------------------------------------- ----- -------- --------
Net cash (used in)/generated from financing
activities (3,230) 2,964
------------------------------------------------- ----- -------- --------
Net decrease in cash and cash equivalents (2,940) (726)
------------------------------------------------- ----- -------- --------
Cash and cash equivalents at beginning
of year 5,918 6,644
------------------------------------------------- ----- -------- --------
Cash and cash equivalents at end of year 2,978 5,918
------------------------------------------------- ----- -------- --------
Company Cash Flow Statement
for the year ended 31 December 2011
Company Company
2011 2010
Note $'000 $'000
--------------------------------------------- ---- -------- -------
Cash flows from operating activities
--------------------------------------------- ---- -------- -------
Loss for the year (7,786) (1,970)
Adjustments for:
Finance expense 1,591 -
Share option compensation charge 289 67
Impairment charge 6 3,071 -
--------------------------------------------- ---- -------- -------
Operating cash flows before movement
in working capital (2,835) (1,903)
(Decrease)/increase in trade and other
payables (185) 78
--------------------------------------------- ---- -------- -------
Cash used in operating activities (3,020) (1,825)
--------------------------------------------- ---- -------- -------
Cash flows from investing activities
Increase in loans to subsidiary undertakings 3,006 1,799
--------------------------------------------- ---- -------- -------
Net cash generated from investing activities 3,006 1,799
--------------------------------------------- ---- -------- -------
Cash flows from financing activities
Proceeds from issue of ordinary share
capital 14 22
Proceeds from ordinary share capital
to be issued - 5
Net cash generated from financing activities 14 27
--------------------------------------------- ---- -------- -------
Net increase/(decrease) in cash and cash
equivalents - 1
Cash and cash equivalents at beginning
of year 10 9
--------------------------------------------- ---- -------- -------
Cash and cash equivalents at end of year 10 10
--------------------------------------------- ---- -------- -------
NOTES TO THE FINANCIAL STATEMENTS
1. Accounting policies and basis of preparation
The final results announcement for the year ended 31 December 2011 has been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union (EU), International Accounting Standards (IAS) and IFRS Interpretations Committee (IFRIC) interpretations and the listing rules of the Financial Services Authority. The details of the significant accounting policies of the Group are set out in the 2011 Annual Report, copies of which are available from the Company or on the Company's website. Based on audited accounts, the financial information set out in this announcement does not constitute the Company's statutory accounts for the year ended 31 December 2011 as defined in Section 434 of the Companies Act 2006, but is derived from those accounts. Statutory accounts for 2010 have been delivered to the Registrar of Companies and those for 2011 will be delivered after the Company's Annual General meeting. The auditors have reported on those accounts; their reports were unqualified and did not contain statements under Section 498(2) or (3) of Companies Act 2006. However included in their report is an emphasis of matter in relation to the basis of preparation in relation to matters as disclosed below.
Going concern
In view of the notices of default having been received from both the holders of the BioSeek notes and Silicon Valley Bank and the lack of interest from parties to acquire the entire share capital of the Company, the Directors have, since the year end, resolved that both the non-BioSeek Tissue Based Solutions and BioSeek businesses should be sold and in due course Asterand plc should be liquidated. Accordingly, the going concern presumption in IAS 1 is not appropriate and the accounts have been drawn up on a basis which reflects the Directors' intention to sell both the non-BioSeek Tissue Based Solutions and BioSeek businesses in an orderly manner in due course, with letters of intent having been signed for the disposal of both businesses. In drawing up the accounts on this basis, the assets of the two businesses are carried at depreciated cost, or if lower, written down to the estimated realisable value based on the offers received for each business. An orderly realisation of the Group's assets is dependent on the continued financial support of Silicon Valley Bank and the BioSeek note holders. No liabilities are required to be recorded in relation to the costs to close down the businesses, as the operating businesses themselves are not being closed but sold.
Impairment of non-current and current assets
Non-current and current assets are tested for impairment when a triggering event occurs by comparing the carrying value of the asset being tested with its recoverable amount. The recoverable amount is the higher of the net selling price and value in use. Value in use is calculated on the basis of estimated future cash flows, using a discount rate appropriate to the Group. If the recoverable amount is less than the carrying amount, an impairment loss is recognised in the income statement. In view of the Directors' decision, post year end, to sell the two businesses in the Tissue Based Solutions segment, impairment charges reflect the net selling price expected to be achieved in these transactions, as value in use is considered to approximate this fair value.
2. Segmental reporting
The Directors are of the opinion that under IFRS 8 'Operating Segments', the Group has two operating segments: Tissue Based Solutions and Licensing. All revenue and costs are recorded in the income statement under these two segments.
The segment information for the year ended 31 December 2011 is as follows:
Group 2011
Tissue Based Licensing Total
Solutions $'000 $'000
$'000
-------------------------------------- -------------- ----------- -------
Revenue from external customers 24,091 - 24,091
-------------------------------------- -------------- ----------- -------
Adjusted EBITDA 1,599 (90) 1,509
-------------------------------------- -------------- ----------- -------
Gross margin 54% - 53%
-------------------------------------- -------------- ----------- -------
Share option related charge 230 - 230
-------------------------------------- -------------- ----------- -------
Depreciation and amortisation 1,084 - 1,084
-------------------------------------- -------------- ----------- -------
Exceptional items 4,733 - 4,733
-------------------------------------- -------------- ----------- -------
Interest income - normal operations 78 - 78
-------------------------------------- -------------- ----------- -------
Interest expense - normal operations 716 - 716
-------------------------------------- -------------- ----------- -------
Interest expense - exceptional
costs 1,591 - 1,591
-------------------------------------- -------------- ----------- -------
Income tax charge 1,627 - 1,627
-------------------------------------- -------------- ----------- -------
Total allocated assets 22,011 - 22,011
-------------------------------------- -------------- ----------- -------
Reduction to non-current assets
(other than financial instruments
and deferred tax assets) 1,904 - 1,904
-------------------------------------- -------------- ----------- -------
The segment information for the year ended 31 December 2010 is as follows:
Group 2010
Tissue Based Licensing Total
Solutions $'000 $'000
$'000
------------------------------------- -------------- ----------- -------
Revenue from external customers 21,291 19 21,310
------------------------------------- -------------- ----------- -------
Adjusted EBITDA 202 (223) (21)
------------------------------------- -------------- ----------- -------
Gross margin 57% - 56%
------------------------------------- -------------- ----------- -------
Share option related charge 132 - 132
------------------------------------- -------------- ----------- -------
Depreciation and amortisation 1,022 - 1,022
------------------------------------- -------------- ----------- -------
Exceptional items 920 - 920
------------------------------------- -------------- ----------- -------
Interest income - normal operations 4 - 4
------------------------------------- -------------- ----------- -------
Interest expense - normal
operations 57 - 57
------------------------------------- -------------- ----------- -------
Income tax charge 32 - 32
------------------------------------- -------------- ----------- -------
Total allocated assets 29,528 - 29,528
------------------------------------- -------------- ----------- -------
Additions to non-current assets
(other than financial instruments
and deferred tax assets) 7,164 - 7,164
------------------------------------- -------------- ----------- -------
A reconciliation of adjusted EBITDA to loss before tax is provided as follows:
2011 2010
$'000 $'000
------------------------------- --- -------- --------
Adjusted EBITDA for total
segments 1,509 (21)
------------------------------------ -------- --------
Share option related charge (230) (132)
------------------------------------ -------- --------
Depreciation and amortisation (1,084) (1,022)
------------------------------------ -------- --------
Exceptional items (4,733) (920)
------------------------------------ -------- --------
Finance (expense)/income (2,063) 54
------------------------------------ -------- --------
Loss before tax (6,601) (2,041)
------------------------------------ -------- --------
Reportable segments' assets are reconciled to total assets as follows:
2011 2010
$'000 $'000
-------------------- --- ------- -------
Segment assets 22,011 29,528
------------------------- ------- -------
Unallocated:
-------------------- --- ------- -------
Deferred tax asset 4,360 4,843
------------------------- ------- -------
Total assets 26,371 34,371
------------------------- ------- -------
During the year the Tissue Based Solutions segment includes revenues derived from a single customer that contributed to 11.2% of total revenues (2010: no single customer exceeded 10% of total revenues).
The licensing revenue for the year ended 31 December 2011 is $nil (2010: $19,000). The Group continues to invest modestly to maintain certain intellectual property in this segment.
The Group operates across four geographical segments. The UK is the home country of the legal parent.
Revenue Revenue Net (liabilities)/assets Capital expenditure
(by destination) (by origin)
2011 2010 2011 2010 2011 2010 2011 2010
$'000 $'000 $'000 $'000 $'000 $'000 $'000 $'000
---------------- ---------- --------- ------- ------- -------------- ----------- ---------- ----------
United Kingdom 2,345 1,356 3,606 3,743 (8,135) (815) 52 70
---------------- ---------- --------- ------- ------- -------------- ----------- ---------- ----------
Rest of Europe 3,643 4,906 - - - - - -
---------------- ---------- --------- ------- ------- -------------- ----------- ---------- ----------
North America 14,141 12,469 20,485 17,567 15,349 15,974 440 305
---------------- ---------- --------- ------- ------- -------------- ----------- ---------- ----------
Japan 3,962 2,579 - - - - - -
---------------- ---------- --------- ------- ------- -------------- ----------- ---------- ----------
24,091 21,310 24,091 21,310 7,214 15,159 492 375
---------------- ---------- --------- ------- ------- -------------- ----------- ---------- ----------
3. Exceptional items
General and administrative items which are significant by virtue of their size or are incidental are classified as exceptional items in the income statement.
Exceptional items comprised the following:
Group Group
2011 2010
$'000 $'000
---------------------------------------------------- -------- ------
Professional fees in relation to acquisition,
restructuring and litigation 184 466
---------------------------------------------------- -------- ------
Severance costs 699 98
---------------------------------------------------- -------- ------
Accelerated share option charge 173 -
Fair value movements on acquisition consideration - 356
Professional fees in relation to sale of businesses 277 -
---------------------------------------------------- -------- ------
Impairment charge in relation to sale of businesses 3,400 -
---------------------------------------------------- -------- ------
4,733 920
---------------------------------------------------- -------- ------
Exceptional legal and professional expenses of $184,000 (2010: $466,000) were incurred during 2011 and are primarily in relation to the Group restructuring. In 2010, these costs related to the acquisition of BioSeek, Inc, litigation to secure access to key procurement sites in Asia and transfer pricing advisory fees.
Severance costs of $699,000 were incurred during 2011; these are costs associated with the Group restructuring (2010: $98,000 relating to the Detroit operations restructuring). In addition, an accelerated fair value share option adjustment of $173,000 is included in 2011 relating to the Growth Share Plan.
Professional fees in relation to the process of selling the Group of $277,000 were incurred during 2011 (2010: $nil), comprising of broker and lawyer fees.
As discussed in the outlook section of the Chairman's Statement, letters of intent to sell both the non-BioSeek Tissue Based Solutions and BioSeek businesses have been signed. Whilst negotiations are on-going, the current expected sales price less costs to sell for the tissue business is such that an impairment charge has been required to write down the carrying value of the assets of the tissue business to the level of the expected net proceeds. The impairment has initially been allocated against goodwill and other intangible assets associated with the relevant cash generating units, with an impairment charge of $1,293,000 being recorded. In addition, since the carrying value of other non-monetary asset classes is considered to materially approximate recoverable amounts, the Directors have re-assessed the carrying value of inventory, such that its value has been reduced by $2,107,000 to reflect the value implied by the expected proceeds for the tissue business as a whole.
For further details surrounding fair value movements on acquisition consideration in 2010, see Note 10.
4. Loss per share
Basic loss per share is calculated by dividing the loss attributable to ordinary shareholders by the weighted average number of 5p Ordinary Shares in issue during the year.
For diluted earnings per share, the weighted average number of Ordinary Shares in issue is adjusted to assume conversion of all potentially dilutive Ordinary Shares.
These represent share options granted to employees where the exercise price is less than the average market price of the Company's Ordinary Shares during the year ended 31 December 2011.
Since 31 December 2011, 112,794 5p ordinary shares have been issued (2010: none).
2011 2010
------------------------------------------- -------- --------
Loss attributable to owners of the parent
($'000s) (8,228) (2,073)
------------------------------------------- -------- --------
Weighted average number of shares (000's) 118,053 115,792
------------------------------------------- -------- --------
Basic loss per Ordinary Share (7.0)c (1.8)c
------------------------------------------- -------- --------
Diluted loss per Ordinary Share (7.0)c (1.8)c
------------------------------------------- -------- --------
In the years ended 31 December 2011 and 31 December 2010, the Group had no potentially dilutive potential Ordinary Shares in issue because it made a loss for the year.
5. Intangible assets
Licences
and
Developed certification Computer
technology costs software Goodwill Total
Group 2011 $'000 $'000 $'000 $'000 $'000
------------------------- ----------- -------------- --------- -------- ------
Cost
At 1 January 2011 3,224 247 237 1,348 5,056
Additions - - 35 - 35
Exchange differences - - 4 - 4
------------------------- ----------- -------------- --------- -------- ------
At 31 December 2011 3,224 247 276 1,348 5,095
------------------------- ----------- -------------- --------- -------- ------
Accumulated amortisation
At 1 January 2011 141 12 125 - 278
Charge for year 161 12 46 - 219
Impairment charge - 223 97 973 1,293
Exchange differences - - - - -
------------------------- ----------- -------------- --------- -------- ------
At 31 December 2011 302 247 268 973 1,790
------------------------- ----------- -------------- --------- -------- ------
Net book value at 31
December 2011 2,922 - 8 375 3,305
------------------------- ----------- -------------- --------- -------- ------
Licences
and
Developed certification Computer
technology costs software Goodwill Total
Group 2010 $'000 $'000 $'000 $'000 $'000
------------------------------- ----------- -------------- --------- -------- ------
Cost
At 1 January 2010 - 231 190 973 1,394
Additions - 23 41 - 64
Assets acquired on acquisition
of BioSeek 3,224 - 11 375 3,610
Exchange differences - (7) (5) - (12)
------------------------------- ----------- -------------- --------- -------- ------
At 31 December 2010 3,224 247 237 1,348 5,056
------------------------------- ----------- -------------- --------- -------- ------
Accumulated amortisation
At 1 January 2010 - - 83 - 83
Charge for year 141 12 42 - 195
Exchange differences - - - - -
------------------------------- ----------- -------------- --------- -------- ------
At 31 December 2010 141 12 125 - 278
------------------------------- ----------- -------------- --------- -------- ------
Net book value at 31
December 2010 3,083 235 112 1,348 4,778
------------------------------- ----------- -------------- --------- -------- ------
Net book value at 1 January
2010 - 231 107 973 1,311
------------------------------- ----------- -------------- --------- -------- ------
The amortisation charge arising on intangible assets other than goodwill for the year of $219,000 (2010: $195,000) has been charged to general and administrative expenses (normal operations).
The Company owns no intangible assets.
As discussed in the outlook section of the Chairman's Statement letters, of intent to sell both the non-BioSeek Tissue Based Solutions and BioSeek businesses have been signed. Whilst negotiations are on-going, the current expected sales price less costs to sell for the non BioSeek Tissue Based Solutions business is such that an impairment charge has been required to write down the carrying value of the assets of the non BioSeek Tissue Based Solutions business to the level of the expected net proceeds. The impairment has initially been allocated against goodwill and other intangible assets associated with the relevant cash generating units, with an impairment charge of $1,293,000 being recorded.
The remaining goodwill of $375,000 arose on the acquisition of the BioSeek business in 2010. The carrying value of goodwill has been assessed based on the higher of fair value less cost to sell and value in use. Based on the offer received for the business, no impairment charge was necessary.
6. Details of principal subsidiaries
Company Company
2011 2010
Fixed asset investments $'000 $'000
--------------------------------------- ------- -------
Shares in Group undertakings
--------------------------------------- ------- -------
As at 1 January 24,574 16,163
------------------------------------------- ------- -------
Capital contribution relating to share
based payments 114 65
------------------------------------------- ------- -------
Acquisition of BioSeek - 8,346
------------------------------------------- ------- -------
Impairment charge (3,071) -
------------------------------------------- ------- -------
As at 31 December 21,617 24,574
------------------------------------------- ------- -------
The capital contribution relates to the share option compensation charge in respect of share options granted by the Company to employees of Asterand UK Limited, Asterand, Inc. and BioSeek, LLC.
Given the intention of the Directors to sell both the non-BioSeek Tissue Based Solutions and BioSeek businesses, they have reviewed the carrying value of investments and recognised an impairment of $3,071,000.
For further details surrounding the acquisition of BioSeek, see Note 10.
Details of subsidiary undertakings are as follows:
Proportion of
nominal value
of issued shares
Description of and voting rights
Name of undertaking Country of incorporation shares held held by the Group
--------------------- -------------------------- ----------------- -------------------
Asterand UK Limited England and Wales ordinary shares 100%
--------------------- -------------------------- ----------------- -------------------
1 cent class A
Asterand, Inc. US common stock 100%
--------------------- -------------------------- ----------------- -------------------
The principal business activity of Asterand UK Limited is the use of human biological information in drug discovery and development. Asterand, Inc.'s principal activity is the collection and supply of human tissue samples to pharmaceutical and biotechnology companies.
Asterand UK Limited owns 100% of the issued share capital of the following company:
Name of undertaking Country of incorporation Description of Principal activities
shares held
------------------------ ------------------------- --------------- ---------------------
Pharmagene Laboratories England and Wales GBP1 ordinary Trustees of the
Trustees Limited shares employee share
ownership plan
------------------------ ------------------------- --------------- ---------------------
Asterand Inc owns 100% of the membership interests of the following company:
Name of undertaking Country of incorporation Description of Principal activities
shares held
----------------------- ------------------------- ------------------- ---------------------
BioSeek, LLC (acquired US 100% of membership Drug discovery
as BioSeek, Inc.) interests services
----------------------- ------------------------- ------------------- ---------------------
All of the above subsidiaries are included in the consolidated accounts and have a year end of 31 December.
7. Biobank inventory
Group Group
2011 2010
$'000 $'000
--------------- ------ ------
Raw materials 1,204 1,016
------------------- ------ ------
Finished goods 5,345 8,120
------------------- ------ ------
6,549 9,136
------------------ ------ ------
The cost of inventories recognised as an expense and included in cost of sales in 2011 amounted to $3,990,329
(2010: $3,611,830).
During 2011, the value of inventories written down to residual value and subsequently included in cost of sales amounted to $1,962,000 (2010: $1,482,000). There is also an obsolescence provision of $449,000 (2010: $449,000) against 'finished goods' to provide against a specific set of specimens that have become delinked from their clinical data.
On 31 December 2011, the carrying value of the biobank inventory was reduced to $6,549,000 due to an impairment charge of $2,107,000 to write down the carrying value of inventory to the amounts implied by the expected recoverable amounts from the sale of the non-BioSeek Tissue Based Solutionsbusiness.
8. Other financial liabilities
Current
Group Group
2011 2010
$'000 $'000
-------------------------------------- ------ ------
Current portion of debt 2,428 703
------------------------------------------ ------ ------
Finance leases 5 12
------------------------------------------ ------ ------
Amounts due to former shareholders of
BioSeek (See Note 10) 6,591 7,624
------------------------------------------ ------ ------
Warrants 12 -
------------------------------------------ ------ ------
9,036 8,339
----------------------------------------- ------ ------
Non-current
Group Group
2011 2010
$'000 $'000
--------------- ------ ------
Long term debt - 2,348
------------------- ------ ------
Finance leases - 5
------------------- ------ ------
- 2,353
------------------ ------ ------
A $3 million three year term loan with Silicon Valley Bank was in drawn down in 2010 and timely repayments have been made throughout 2011. The loan bears interest at 3.25% above the Prime Rate and 5.0% above Prime Rate when in default. At 31 December 2011 the Group had breached covenants attaching to its Silicon Valley Bank loan and loan notes borrowings, such that these amounts became payable on demand.
The loan arrangement fees for the term loan have been deducted from the amounts borrowed and are being amortised over a three year period.
Finance lease liabilities
Group Group
2011 2010
Gross finance lease liabilities - minimum
lease payments $'000 $'000
------------------------------------------ ----- -----
No later than one year 6 15
------------------------------------------ ----- -----
Later than one year and no later than
five years - 5
------------------------------------------ ----- -----
6 20
------------------------------------------ ----- -----
Future finance charges on finance leases (1) (3)
------------------------------------------ ----- -----
Present value of finance leases 5 17
------------------------------------------ ----- -----
The present value of finance lease liabilities is as follows:
Group Group
2011 2010
$'000 $'000
-------------------------------------- ------ ------
No later than one year 5 12
------------------------------------------ ------ ------
Later than one year and no later than
five years - 5
------------------------------------------ ------ ------
5 17
----------------------------------------- ------ ------
9. Related party transactions
The Group did not enter into any related party transactions during the year.
During 2010, the Group paid $117,000 on behalf of Martyn Coombs, former CEO, to cover the taxes payable on his Growth Share Ownership Plan implemented during the year. This amount was subsequently reimbursed and was fully repaid by 31 December 2010.
The Company entered into the following transactions in the year with subsidiaries of the Group:
Company Company
2011 2010
Intercompany receivable/(payable) $'000 $'000
---------------------------------- -------- -------
At 1 January 3,001 4,767
-------------------------------------- -------- -------
Amounts received (5,330) (1,766)
-------------------------------------- -------- -------
At 31 December (2,329) 3,001
-------------------------------------- -------- -------
10. BioSeek acquisition
The Group acquired 100% of the share capital of BioSeek, Inc. ("BioSeek") on 18 February 2010.
The initial consideration paid by Asterand was a sum of $1.0 million satisfied by the issue of 2,695,856 New Asterand Shares at $0.37 (22p) per share - calculated based on the per share closing prices of Ordinary Shares on the London Stock Exchange during the thirty (30) consecutive trading day period ended on 17 November 2009, converted into U.S. dollars at the exchange rate for purchasing U.S. dollars with pound sterling as quoted in the Financial Times on such date.
An additional sum of $8.5 million became payable in April 2011 based on a formula applied to 2010 BioSeek revenues.
As previously announced, the first US $3 million of this payment was to be satisfied through the issue of 8.1 million Asterand shares, and the remaining $5.5 million consideration was to be paid in cash. All amounts recorded at the 31 December 2010 balance sheet date (valued under IFRS 3 (revised), 'Business combinations') were made under this assumption.
However, in April 2011 the Group subsequently agreed with the former BioSeek shareholders that the entire $8.5 million of contingent consideration would be satisfied with cash rather than cash and shares; $2.5 million was paid in July 2011 and the remaining $6 million to be satisfied by the issue of loan notes ("Amounts due to former shareholders of BioSeek") that mature over the period to December 2013. The Company has entered into a warrant agreement with the former BioSeek shareholders whereby they have the right to subscribe for 5.2 million new Ordinary Shares at 14.12p per share. This warrant agreement will expire on 22 July 2014.
The contingent consideration was classified as a financial liability under IFRS 3 (revised). Under IAS 39, 'Financial instruments: Recognition and measurement', the change in the settlement of debt to the former shareholders of BioSeek has been treated as an extinguishment of the original financial liability on the balance sheet. As a result, the fair value of the re-negotiated debt is recorded as a liability on the balance sheet, with the movement in fair value being recorded through the income statement. The fair value of the cash and loan notes at inception was $8,968,000. These financial liabilities have been designated at inception at fair value through profit or loss and therefore they will be recorded at their fair value each reporting period, with subsequent changes in fair value also being recorded through the income statement. The fair value of the loan notes at 31 December 2011 was $6,537,000.
Under IFRS, warrants with an exercise price denominated in a currency (GBP) different to that of the Company's functional currency (USD) should be recorded at their fair value within liabilities, with changes in their fair value recorded through the income statement. The fair value of the warrants was initially recorded at $716,000. The warrants will continue to be adjusted through the income statement each reporting period until such time as they are exercised or expire. The fair value of the warrants at 31 December 2011 was $54,000.
The movement in fair value between these financial liabilities and their subsequent re-measurement at the balance sheet date has been recorded as exceptional interest expense as follows:
Other financial liabilities
- amounts due to former shareholders of BioSeek
31 December 31 December Change in
2011 2010 Fair value
$'000 $'000 $'000
--------------------------------------- ----------- ----------- -----------
Fair value of contingent consideration - 7,624 7,624
------------------------------------------- ----------- ----------- -----------
Fair value of cash and loan notes
at inception 8,968 - (8,968)
------------------------------------------- ----------- ----------- -----------
Re-measurement of loan notes
to fair value 193 - (193)
------------------------------------------- ----------- ----------- -----------
Initial fair value of warrants 716 - (716)
------------------------------------------- ----------- ----------- -----------
Re-measurement of warrants to
fair value (662) - 662
------------------------------------------- ----------- ----------- -----------
Interest expense - exceptional
costs (1,591)
------------------------------------------- ----------- ----------- -----------
The warrants have been classified within current financial liabilities.
11. Post balance sheet events
The Directors have resolved that both the non-BioSeek Tissue Based Solutions and BioSeek businesses should be sold, with letters of intent having been signed for the disposal of both businesses. Both of these businesses form part of the Tissue Based Solutions segment. The disposal of each of these businesses is considered to be a class 1 disposal, and will therefore require shareholder approval, but the Directors expect the sale to complete by 30 June 2012.
Notice of Annual General Meeting
-- Asterand Plc will hold its Annual General Meeting at its registered office at 2 Orchard Road, Royston, Hertfordshire, SG8 5HD on Tuesday 26 June 2012 at 10:00 am.
The following documents have been sent to shareholders today:
-- Annual Report and Accounts 2011
-- Notice of 2012 Annual General Meeting ('AGM')
-- Form of Proxy
In accordance with Listing Rule 9.6.1 Asterand Plc has submitted two copies of each of the above documents to the UK Listing Authority ('UKLA') and these documents will shortly be available for inspection at the UKLA's Document Viewing Facility, which is situated at: Financial Services Authority 25 The North Colonnade Canary Wharf London E14 5HS Tel: +44 (0) 20 7066 1000. Copies of the Annual Report and Accounts 2011 and Notice of AGM, will be available on the Company's website at www.asterand.com on 30 April 2012. For further information contact:
Jack Davis, Chairman, Interim CEO and Company Secretary
Tel No: +44 (0) 1763 211600
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR BKLFLLZFEBBE
1 Year Bioseek Chart |
1 Month Bioseek Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
